Brian M. Alexander, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA; and Timothy F. Cloughesy, University of California Los Angeles, Los Angeles, CA.
J Clin Oncol. 2017 Jul 20;35(21):2402-2409. doi: 10.1200/JCO.2017.73.0119. Epub 2017 Jun 22.
Glioblastoma (GBM) is a rare tumor and one of the most challenging malignancies to treat in all of oncology. Although advances have been made in the treatment of GBM, encouraging outcomes typically are not observed; patients diagnosed with these tumors generally have a dismal prognosis and poor quality of life as the disease progresses. This review summarizes the clinical presentation of GBM, diagnostic methods, evidentiary basis for the current standards of care, and investigational approaches to treat or manage GBM. Because the track record for developing effective therapies for GBM has been dismal, we also review the challenges to successful therapeutic and biomarker development.
胶质母细胞瘤(GBM)是一种罕见的肿瘤,也是肿瘤学中最难治疗的恶性肿瘤之一。尽管在 GBM 的治疗方面取得了进展,但通常观察不到令人鼓舞的结果;被诊断患有这些肿瘤的患者通常预后不良,随着疾病的进展,生活质量较差。本综述总结了 GBM 的临床表现、诊断方法、当前治疗标准的证据基础以及治疗或管理 GBM 的研究方法。由于为 GBM 开发有效疗法的记录不佳,我们还回顾了成功治疗和生物标志物开发所面临的挑战。